● Recruiting

Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic Function

Condition: Hepatic Impairment and Healthy Female · Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

PhasePhase 1

Planned participants24

Who can joinAll sexes, 18 Years to 79 Years

Healthy volunteersYes

About this study

This study is a Phase I, single-dose, open-label trial designed to evaluate the pharmacokinetics and safety of a single oral dose of 25 mg VC005 tablets in participants with mild and moderate hepatic impairment compared to participants with normal hepatic function.

This description comes directly from the study's public registry record.

Talk to the study team

xiaojuan lai · 15358160458 · lai_xiaojuan@vcarepharmatech.com

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital of Bengbu Medical University

Bengbu, Anhui, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07551557